Your shopping cart is currently empty

DG-041 is an antagonist of high affinity EP3 receptor (IC50s: 4.6 nM and 8.1 nM in the binding and FLIPR assay, respectively ). DG-041 inhibits PGE2 facilitation of platelet aggregation and it also crosses the blood-brain barrier.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $43 | In Stock | In Stock | |
| 2 mg | $61 | In Stock | In Stock | |
| 5 mg | $98 | In Stock | In Stock | |
| 10 mg | $162 | In Stock | In Stock | |
| 25 mg | $316 | In Stock | In Stock | |
| 50 mg | $568 | In Stock | In Stock | |
| 100 mg | $818 | In Stock | In Stock | |
| 500 mg | $1,690 | 6-8 weeks | 6-8 weeks | |
| 1 mL x 10 mM (in DMSO) | $112 | In Stock | In Stock |
| Description | DG-041 is an antagonist of high affinity EP3 receptor (IC50s: 4.6 nM and 8.1 nM in the binding and FLIPR assay, respectively ). DG-041 inhibits PGE2 facilitation of platelet aggregation and it also crosses the blood-brain barrier. |
| Targets&IC50 | EP3 receptor:4.6/8.1 nM |
| In vitro | DG-041 was a less effective the DP1 (IC50: 131 nM), EP1 (IC50: 486 nM) and TP receptors (IC50: 742 nM) antagonist [1]. |
| In vivo | DG-041 has CL of 1250 mL/h/kg for intravenous. DG-041 (1.78 mg/kg for i.v or 9.62 mg/kg for p.o) has t1/2 of 2.7 hours, 4.06 hours. DG-041 (1.78 mg/kg for i.v or 9.62 mg/kg for p.o) has Cmax of 9.46 μM, 2.74 μM for intravenous and oral administration, respectively [1]. |
| Molecular Weight | 592.32 |
| Formula | C23H15Cl4FN2O3S2 |
| Cas No. | 861238-35-9 |
| Smiles | Cc1cn(Cc2ccc(Cl)cc2Cl)c2c(\C=C\C(=O)NS(=O)(=O)c3cc(Cl)c(Cl)s3)cc(F)cc12 |
| Relative Density. | 1.57 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (92.86 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.38 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.